NUTRITION IN IBD PATIENT'S: WHAT ARE THE PROSPECTS?

Attilio Ignazio Lo Monte, Claudia Campanella, Giovanni Tomasello, Emanuele Sinagra, Giuseppe Damiano, Francesco Damiani, Antonella Marino Gammazza, Francesca Rappa, Alida Abruzzo, Vincenzo Davide Palumbo, Claudia Campanella, Antonella Marino Gammazza, Emanuele Sinagra, Francesca Rappa, Giovanni Tomasello, Vincenzo Davide Palumbo, Giovanna Traina

Risultato della ricerca: Article

6 Citazioni (Scopus)

Abstract

Summary: Inflammatory Bowel Disease (IBD) is a chronic disorder characterized by a relapsing-remitting course, which alternates between active and quiescent states, ultimately impairing a patients quality of life. The two main types of IBD are Crohn's disease (CD) and Ulcerative Colitis (UC). In physiological conditions the gut is costantly exposed to various antigens, commensal microflora and pathogens and the inflammatory response is finely balanced. It is thought that a vast number of environmental risk factors may be implicated in the development of IBD, including smoking factors, dietary factors, psycological stress, use of non-steroidal anti-inflammatory drugs and oral contraceptives, appendicectomy, breastfeeding, as well as infections. Nutritional support, as a primary therapy, has a crucial role in the management of patients with IBD. The gut microbiota is clearly manipulated by dietary components such as n-3 polyunsatured fatty acids (n-3 PUFA) and coniugated linoleic acid (CLA) which favorably reduce endotoxin load via shifts in the composition and metabolic activity of the microbial community. in particular, the beneficial effect of n-3 PUFAs and fermentable fiber, during the remission/quiescent phase of both CD and UC is Highlighted. In fact, PUFAs are associated with a less grade of inflammation since they are metabolized to 3-series prostagliandins and thromboxanes and 5-series leukotrienes and, in addition, exert antiinflammatory effects when compared with their n-6 PUFA counterparts. In similar action to dietary n-3 PUFA, coniugated linoleic acid (CLA) have been reported to ameliorate intestinal inflammation in animal models of IBD. Currently, is still unclear the role of the fibers in helping the remission of the disease. Data about the consumption of fiber are controversial. On one hand, dietary fibers can act as effective prebiotics by altering the intestinal microbial composition and promoting the growth of beneficial bacterial communities within the large intestine. On the other hand, fibers can promote diarrhea, pain and gas aggravating the clinical sate. Cocnclusion: We suggest that the consumption of fermentable fibers may have a good impact on patient's health.
Lingua originaleEnglish
pagine (da-a)79-86
Numero di pagine8
RivistaProgress in Nutrition
Volume17
Stato di pubblicazionePublished - 2015

Fingerprint

inflammatory bowel disease
Inflammatory Bowel Diseases
dietary fiber
nutrition
Omega-3 Fatty Acids
Linoleic Acid
Ulcerative Colitis
Crohn disease
Crohn Disease
inflammation
colitis
remission
Anti-Inflammatory Agents
omega-3 fatty acids
linoleic acid
Inflammation
Prebiotics
Nutritional Support
Leukotrienes
Thromboxanes

All Science Journal Classification (ASJC) codes

  • Food Science
  • Nutrition and Dietetics

Cita questo

NUTRITION IN IBD PATIENT'S: WHAT ARE THE PROSPECTS? / Lo Monte, Attilio Ignazio; Campanella, Claudia; Tomasello, Giovanni; Sinagra, Emanuele; Damiano, Giuseppe; Damiani, Francesco; Marino Gammazza, Antonella; Rappa, Francesca; Abruzzo, Alida; Palumbo, Vincenzo Davide; Campanella, Claudia; Gammazza, Antonella Marino; Sinagra, Emanuele; Rappa, Francesca; Tomasello, Giovanni; Palumbo, Vincenzo Davide; Traina, Giovanna.

In: Progress in Nutrition, Vol. 17, 2015, pag. 79-86.

Risultato della ricerca: Article

Lo Monte, Attilio Ignazio ; Campanella, Claudia ; Tomasello, Giovanni ; Sinagra, Emanuele ; Damiano, Giuseppe ; Damiani, Francesco ; Marino Gammazza, Antonella ; Rappa, Francesca ; Abruzzo, Alida ; Palumbo, Vincenzo Davide ; Campanella, Claudia ; Gammazza, Antonella Marino ; Sinagra, Emanuele ; Rappa, Francesca ; Tomasello, Giovanni ; Palumbo, Vincenzo Davide ; Traina, Giovanna. / NUTRITION IN IBD PATIENT'S: WHAT ARE THE PROSPECTS?. In: Progress in Nutrition. 2015 ; Vol. 17. pagg. 79-86.
@article{4f123ecab0c54c36835753d54c56da5a,
title = "NUTRITION IN IBD PATIENT'S: WHAT ARE THE PROSPECTS?",
abstract = "Summary: Inflammatory Bowel Disease (IBD) is a chronic disorder characterized by a relapsing-remitting course, which alternates between active and quiescent states, ultimately impairing a patients quality of life. The two main types of IBD are Crohn's disease (CD) and Ulcerative Colitis (UC). In physiological conditions the gut is costantly exposed to various antigens, commensal microflora and pathogens and the inflammatory response is finely balanced. It is thought that a vast number of environmental risk factors may be implicated in the development of IBD, including smoking factors, dietary factors, psycological stress, use of non-steroidal anti-inflammatory drugs and oral contraceptives, appendicectomy, breastfeeding, as well as infections. Nutritional support, as a primary therapy, has a crucial role in the management of patients with IBD. The gut microbiota is clearly manipulated by dietary components such as n-3 polyunsatured fatty acids (n-3 PUFA) and coniugated linoleic acid (CLA) which favorably reduce endotoxin load via shifts in the composition and metabolic activity of the microbial community. in particular, the beneficial effect of n-3 PUFAs and fermentable fiber, during the remission/quiescent phase of both CD and UC is Highlighted. In fact, PUFAs are associated with a less grade of inflammation since they are metabolized to 3-series prostagliandins and thromboxanes and 5-series leukotrienes and, in addition, exert antiinflammatory effects when compared with their n-6 PUFA counterparts. In similar action to dietary n-3 PUFA, coniugated linoleic acid (CLA) have been reported to ameliorate intestinal inflammation in animal models of IBD. Currently, is still unclear the role of the fibers in helping the remission of the disease. Data about the consumption of fiber are controversial. On one hand, dietary fibers can act as effective prebiotics by altering the intestinal microbial composition and promoting the growth of beneficial bacterial communities within the large intestine. On the other hand, fibers can promote diarrhea, pain and gas aggravating the clinical sate. Cocnclusion: We suggest that the consumption of fermentable fibers may have a good impact on patient's health.",
author = "{Lo Monte}, {Attilio Ignazio} and Claudia Campanella and Giovanni Tomasello and Emanuele Sinagra and Giuseppe Damiano and Francesco Damiani and {Marino Gammazza}, Antonella and Francesca Rappa and Alida Abruzzo and Palumbo, {Vincenzo Davide} and Claudia Campanella and Gammazza, {Antonella Marino} and Emanuele Sinagra and Francesca Rappa and Giovanni Tomasello and Palumbo, {Vincenzo Davide} and Giovanna Traina",
year = "2015",
language = "English",
volume = "17",
pages = "79--86",
journal = "Progress in Nutrition",
issn = "1129-8723",
publisher = "Mattioli 1885 S.p.A.",

}

TY - JOUR

T1 - NUTRITION IN IBD PATIENT'S: WHAT ARE THE PROSPECTS?

AU - Lo Monte, Attilio Ignazio

AU - Campanella, Claudia

AU - Tomasello, Giovanni

AU - Sinagra, Emanuele

AU - Damiano, Giuseppe

AU - Damiani, Francesco

AU - Marino Gammazza, Antonella

AU - Rappa, Francesca

AU - Abruzzo, Alida

AU - Palumbo, Vincenzo Davide

AU - Campanella, Claudia

AU - Gammazza, Antonella Marino

AU - Sinagra, Emanuele

AU - Rappa, Francesca

AU - Tomasello, Giovanni

AU - Palumbo, Vincenzo Davide

AU - Traina, Giovanna

PY - 2015

Y1 - 2015

N2 - Summary: Inflammatory Bowel Disease (IBD) is a chronic disorder characterized by a relapsing-remitting course, which alternates between active and quiescent states, ultimately impairing a patients quality of life. The two main types of IBD are Crohn's disease (CD) and Ulcerative Colitis (UC). In physiological conditions the gut is costantly exposed to various antigens, commensal microflora and pathogens and the inflammatory response is finely balanced. It is thought that a vast number of environmental risk factors may be implicated in the development of IBD, including smoking factors, dietary factors, psycological stress, use of non-steroidal anti-inflammatory drugs and oral contraceptives, appendicectomy, breastfeeding, as well as infections. Nutritional support, as a primary therapy, has a crucial role in the management of patients with IBD. The gut microbiota is clearly manipulated by dietary components such as n-3 polyunsatured fatty acids (n-3 PUFA) and coniugated linoleic acid (CLA) which favorably reduce endotoxin load via shifts in the composition and metabolic activity of the microbial community. in particular, the beneficial effect of n-3 PUFAs and fermentable fiber, during the remission/quiescent phase of both CD and UC is Highlighted. In fact, PUFAs are associated with a less grade of inflammation since they are metabolized to 3-series prostagliandins and thromboxanes and 5-series leukotrienes and, in addition, exert antiinflammatory effects when compared with their n-6 PUFA counterparts. In similar action to dietary n-3 PUFA, coniugated linoleic acid (CLA) have been reported to ameliorate intestinal inflammation in animal models of IBD. Currently, is still unclear the role of the fibers in helping the remission of the disease. Data about the consumption of fiber are controversial. On one hand, dietary fibers can act as effective prebiotics by altering the intestinal microbial composition and promoting the growth of beneficial bacterial communities within the large intestine. On the other hand, fibers can promote diarrhea, pain and gas aggravating the clinical sate. Cocnclusion: We suggest that the consumption of fermentable fibers may have a good impact on patient's health.

AB - Summary: Inflammatory Bowel Disease (IBD) is a chronic disorder characterized by a relapsing-remitting course, which alternates between active and quiescent states, ultimately impairing a patients quality of life. The two main types of IBD are Crohn's disease (CD) and Ulcerative Colitis (UC). In physiological conditions the gut is costantly exposed to various antigens, commensal microflora and pathogens and the inflammatory response is finely balanced. It is thought that a vast number of environmental risk factors may be implicated in the development of IBD, including smoking factors, dietary factors, psycological stress, use of non-steroidal anti-inflammatory drugs and oral contraceptives, appendicectomy, breastfeeding, as well as infections. Nutritional support, as a primary therapy, has a crucial role in the management of patients with IBD. The gut microbiota is clearly manipulated by dietary components such as n-3 polyunsatured fatty acids (n-3 PUFA) and coniugated linoleic acid (CLA) which favorably reduce endotoxin load via shifts in the composition and metabolic activity of the microbial community. in particular, the beneficial effect of n-3 PUFAs and fermentable fiber, during the remission/quiescent phase of both CD and UC is Highlighted. In fact, PUFAs are associated with a less grade of inflammation since they are metabolized to 3-series prostagliandins and thromboxanes and 5-series leukotrienes and, in addition, exert antiinflammatory effects when compared with their n-6 PUFA counterparts. In similar action to dietary n-3 PUFA, coniugated linoleic acid (CLA) have been reported to ameliorate intestinal inflammation in animal models of IBD. Currently, is still unclear the role of the fibers in helping the remission of the disease. Data about the consumption of fiber are controversial. On one hand, dietary fibers can act as effective prebiotics by altering the intestinal microbial composition and promoting the growth of beneficial bacterial communities within the large intestine. On the other hand, fibers can promote diarrhea, pain and gas aggravating the clinical sate. Cocnclusion: We suggest that the consumption of fermentable fibers may have a good impact on patient's health.

UR - http://hdl.handle.net/10447/141492

M3 - Article

VL - 17

SP - 79

EP - 86

JO - Progress in Nutrition

JF - Progress in Nutrition

SN - 1129-8723

ER -